Related references
Note: Only part of the references are listed.Idelalisib for the treatment of non-Hodgkin lymphoma
Solomon A. Graf et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Update on Burkitt Lymphoma
Kieron Dunleavy et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2016)
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer
M. R. Sheen et al.
ONCOGENESIS (2016)
Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes
Andrew Davies
EXPERT REVIEW OF HEMATOLOGY (2015)
The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells
G. Wan et al.
CELL DEATH DISCOVERY (2015)
Oncogenic Mechanisms in Burkitt Lymphoma
Roland Schmitz et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
Filip Janku et al.
CANCER RESEARCH (2013)
PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
Sarah A. Meadows et al.
BLOOD (2012)
The genetic landscape of mutations in Burkitt lymphoma
Cassandra Love et al.
NATURE GENETICS (2012)
PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
Filip Janku et al.
ONCOTARGET (2012)
Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics:: correlation with morphology, immunology and clinical features
T Burmeister et al.
LEUKEMIA (2005)
Share Paper
